AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02490696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miso PET scan
Description: 2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
Study NCT03242954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autonomous minor consent
Description: Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
Study NCT02272556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRS during hyperglycemic clamp
Description: All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
Study NCT02272556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of Metabolites in cerebrospinal fluid
Description: All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
Study NCT04910178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: tablets to be taken orally once a day
Study NCT02490696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FAZA PET scan
Description: 2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
Study NCT04672109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
Study NCT04910178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: tablets to be taken orally twice a day
Study NCT03242954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult permission required
Description: Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
Study NCT03242954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parental permission required
Description: Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
Study NCT04910178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: tablets to be taken orally twice a day
Study NCT04910178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: just starch tablets without any active agents
Study NCT00906165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann® Bone Level SLActive Implant (4.1mm diameter)
Description: Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
Study NCT03101540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
Study NCT01110005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5 Lactated Ringer's Solution (D5LR)
Description: D5LR IV fluid
Study NCT01110005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution (LR)
Description: LR IV fluid
Study NCT04091893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care/wait list
Description: Individuals in this group can continue with their usual care (but receive no museum-based intervention)
Study NCT04672109 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
Study NCT02807246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Maflor®, Mamsel Pharmaceuticals, Turkey
Description: Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®
Study NCT02807246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drops of saline
Description: Dietary Supplement: Breast milk +drops of saline
Study NCT01839357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
Study NCT02678520 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-D Conformal Radiation Therapy
Description: Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
Study NCT04091893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Rx
Description: Individuals in this group participate in a specialized tour of an art museum
Study NCT01246076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT00609830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Materials
Description: Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
Study NCT02678520 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
Study NCT04091893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artful Meditation
Description: Individuals in this group participate in a meditation and art appreciation program at an art museum
Study NCT03890809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study NCT02678520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex, Zoladex , Lupron
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
Study NCT02678520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex, Zoladex , Lupron
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
Study NCT01427621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic pre and postconditioning (RIPC)
Description: RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
Study NCT00994474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional carbon dioxide laser treatment
Description: With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
Study NCT00994474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Er:YAG laser treatment
Description: The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
Study NCT00609830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Materials Plus Physician Feedback
Description: Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
Study NCT02441361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training will comprise aerobic and strength exercises
Study NCT01930786 — intervention group
Intervention type: DRUG
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Study NCT04883593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA103
Description: The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
Study NCT00910975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Copegus)
Description: Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
Study NCT04883593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
Study NCT01594177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 20 mg daily for 17 weeks (first two weeks every second day).
Study NCT01594177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
Study NCT01594177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
Study NCT01594177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
Study NCT01594177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
Study NCT00609830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Materials
Description: Participants received generic written educational materials about osteoporosis prevention.
Study NCT04765293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy Gravity strengthening exercises vs standard physical therapy
Study NCT00609830 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Information
Description: Participants received no informational materials.
Study NCT01349374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
Study NCT06249971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermal subsitute Glyaderm + skin graft
Description: A human donor-derived dermal substitute will be implanted together with a skin graft
Study NCT06249971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin graft alone
Description: Skin graft alone with no dermal substitute
Study NCT04765293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical Therapy Gravity strengthening exercises vs standard physical therapy
Study NCT03133663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram group
Description: Experimental
Study NCT03133663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximeter and auscultation group
Description: Control
Study NCT04668287 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increasing self-esteem
Description: During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
Study NCT01945567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Up to 3 mA, 60 us, 130 Hz deep brain stimulation
Study NCT01945567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empirical unblinded deep brain stimulation programming
Study NCT01503138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purpose-built intervention
Description: A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
Study NCT01235676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: calorie restriction to reduce weight gain
Study NCT00698321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD prevention curriculum
Description: The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
Study NCT00698321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health promotion curriculum
Description: The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
Study NCT03871049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with dexamethasone
Description: bupivacaine with dexamethasone
Study NCT01235676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise to reduce weight gain
Study NCT03871049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study NCT01682005 — intervention group
Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
Study NCT03752125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid, caffeine
Description: 2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
Study NCT03752125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules before breakfast, 2 capsules before lunch
Study NCT04917783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passport Card
Description: After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report.
Study NCT04917783 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Passport card
Description: After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
Study NCT02773797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IN-DEX 1.0 mcg/kg, intranasal saline
Study NCT02773797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IN-DEX 1.5 mcg/kg, intranasal saline
Study NCT02773797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Saline
Study NCT04057716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to restrict their time in bed to 8 hours each night for one week.
Study NCT03504826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Description: Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
Study NCT05332860 — intervention group
Intervention type: PROCEDURE
Intervention: Congenital Cardiovascular Surgery
Description: Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
Study NCT03777501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-random whole body vibration
Description: Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
Study NCT03777501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy
Description: Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
Study NCT03286972 — intervention group
Intervention type: DEVICE
Intervention: PET/MRI
Description: Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
Study NCT04257331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme
Description: The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
Study NCT05668247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOOT BATH
Description: In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.